Signal
FDA approves Rocket's first gene therapy for severe leukocyte adhesion deficiency type I
Evidence first: scan the strongest sources, then decide whether to go deeper.
rss
clinical_trialsfdaapprovalsdrug_developmentsafety_signals
Trend in the last 24h
Source links limited
You can inspect the signal and top sources here. Full source links and workflow tools unlock on the flagship sample or in the app.
Evidence preview
- FDA Press Releasesfda.gov
- Rocket has announced that the FDA signed off on an accelerated approval for its hematopoietic stem cell-based gene th...Fierce Pharma (All)
- Rocket gene therapy cleared by FDA for rare immune disorderBioPharma Dive
- Touchdown for Rocket as its first gene therapy gets US okaypharmaphorum
Overview
The FDA has granted accelerated approval to Kresladi (marnetegragene autotemcel), Rocket Pharmaceuticals' hematopoietic stem cell-based gene therapy for treating children with severe leukocyte adhesion deficiency type I (LAD-I).
Entities
Rocket PharmaceuticalsKresladimarnetegragene autotemcel
Score total
1.52
Momentum 24h
4
Posts
4
Origins
4
Source types
1
Duplicate ratio
0%
Why now
- Approval follows Rocket's recent submission and regulatory review.
- Accelerated approval enables earlier patient access to this novel therapy.
- Highlights ongoing progress in gene therapy development and rare disease treatment.
Why it matters
- First gene therapy approved for severe leukocyte adhesion deficiency type I, a rare immune disorder.
- Represents a significant advancement in gene therapy for rare diseases.
- Marks a positive regulatory milestone for Rocket Pharmaceuticals after prior setbacks.
LLM analysis
Topic mix: lowPromo risk: lowSource quality: high
Recurring claims
- FDA approved Kresladi as the first gene therapy for severe leukocyte adhesion deficiency type I
How sources frame it
- FDA: neutral
- BioPharma Dive: neutral